NEW YORK, June 30 - Ciphergen Biosystems and diagnostics firm BioMerieux have entered a collaboration using Ciphergen's ProteinChip technology to discover biomarkers that may improve the diagnosis and management of colon cancer, Ciphergen said today.
Ciphergen will install its technology platform at BioMerieux's Marcy-l'Etoile, France, site and the company's Biomarker Discovery Center team will collaborate with BioMerieux's research team.
Financial terms of the agreement were not disclosed.